All In Biotech

Drug Trial Radar · NCT01972841

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder

A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder

Last checked: Nov 19, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,527 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,527

Actual

Start

Nov 5, 2013

Primary completion

Oct 22, 2015

Study completion Oct 22, 2015

Sponsor

Lead sponsor
Astellas Pharma Europe B.V.Astellas (ALPMY)
Sponsor type
Industry
First posted
Oct 31, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to examine how well two medicines (solifenacin succinate and mirabegron) combined work compared to each medicine alone in the treatment of bladder problems.

Conditions

  • Urinary Bladder Overactive
  • Urinary Bladder Diseases\Urologic Diseases
  • Overactive Bladder
  • Urgency Incontinence

Interventions

  • Solifenacin succinateDrug

    Oral tablet

  • MirabegronDrug

    Oral tablet

  • Placebo to match solifenacin succinateDrug

    Oral tablet

  • Placebo to match mirabegronDrug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 HoursTime frame: Baseline and EoT (up to 12 weeks)
  2. Change From Baseline to EoT in Mean Number of Micturitions Per 24 HoursTime frame: Baseline and EoT (up to 12 weeks)

Locations

435 sites in 42 countries. Site status is shown where the registry gives one.

  • Site US10049 Coastal Clinical Research, Inc.

    Mobile, Alabama

  • Site US10112 TFI, LLC

    Mobile, Alabama

  • Site US10104 Clinical Research Advantage, Inc.

    Chandler, Arizona

  • Site US10021 Beach Clinical Studies

    Phoenix, Arizona

  • Site US10122 Orange County Research Institute

    Anaheim, California

  • Site US10098 Skyline Research

    Cerritos, California

  • Site US10539 Citrus Valley Medical Research

    Glendora, California

  • Site US10082 American Clinical Trials

    Hawaiian Gardens, California

  • Site US10132 Axis Clinical Trials

    Los Angeles, California

  • Site US10133 Axis Clinical Trials

    Los Angeles, California

  • Site US10536 Stanford School of Medicine

    Palo Alto, California

  • Site US10149 Bayview Research Group

    Paramount, California

  • Site US10559 UC Davis Medical Center

    Sacramento, California

  • Site US10003 San Diego Clinical Trials

    San Diego, California

  • Site US10545 San Diego Institute for Sexual Medicine

    San Diego, California

  • Site US10106 West Coast Clinical Research

    Tarzana, California

  • Site US10595 Bayview Research Group

    Valley Village, California

  • Site US10034 Urology Center of Colorado

    Denver, Colorado

  • Site US10070 Physicians' Research Options/Red Rocks OB/GYN

    Lakewood, Colorado

  • Site US10053 Western Clinical Research, Inc.

    Wheat Ridge, Colorado

  • Site US10128 Clinical Research Center of CT

    Danbury, Connecticut

  • Site US10018 Grove Hill Clinical Research

    New Britain, Connecticut

  • Site US10170 Yale - New Haven Hospital West Haven VAMC

    New Haven, Connecticut

  • Site US10123 Chase Medical Research, LLC

    Waterbury, Connecticut

  • Site US10060 Meridien Research

    Bradenton, Florida

  • Site US10097 A.G.A. Clinical Trials DBA Neostart Group

    Hialeah, Florida

  • Site US10148 Best Quality Research, Inc.

    Hialeah, Florida

  • Site US10153 Palmetto Professional Research

    Hialeah, Florida

  • Site US10159 Urological Research Network

    Hialeah, Florida

  • Site US10534 South Florida Medical Research

    Hialeah, Florida

  • Site US10535 South Florida Medical Research

    Homestead, Florida

  • Site US10165 East Coast Institute for Research

    Jacksonville, Florida

  • Site US10091 Health Awareness

    Jupiter, Florida

  • Site US10150 Suncoast Clinical Research, Inc.

    New Port Richey, Florida

  • Site US10158 Renstar Medical Research

    Ocala, Florida

  • Site US10124 Winter Park Urology Associates

    Orlando, Florida

  • Site US10134 Compass Research, LLC

    Orlando, Florida

  • Site US10009 South Broward Research

    Pembroke Pines, Florida

  • Site US10540 Demaur Clinical Research, INC

    Pembroke Pines, Florida

  • Site US10554 Private Practice

    Plantation, Florida

Showing 40 of 435 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.